InvestorsHub Logo
Followers 23
Posts 2341
Boards Moderated 0
Alias Born 03/15/2007

Re: BioBS2012 post# 190367

Tuesday, 09/16/2014 12:41:33 PM

Tuesday, September 16, 2014 12:41:33 PM

Post# of 345968
S.King’s 9-9-05 Letter to Shareholders
“As an example, we have seen a significant amount of interest building in the anti-phospholipid therapy program and particularly in Tarvacin over the past year from potential partners as the program has entered into clinical trials.”


Just a little more patience and these potential partners will emerge.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News